Hpv Virus - Research

Lonky NM, Felix J, Tsadik GW, Lonky S. Department of Obstetrics and Gynecology, Kaiser Permanente, Anaheim, CA, USA.

OBJECTIVE: We investigated the detection of high-risk human papillomavirus DNA with the Hybrid Capture II test (HCII; Digene Corporation, Beltsville, MD) and the presence and pattern of distribution of adhesion molecules in biopsy-proven high-grade neoplastic lesions containing high-risk HPV-DNA from women with ASC cytology results. MATERIALS AND METHODS: We screened 4,600 women and performed colposcopy in 278 women with atypical squamous cells cytologic results. All women underwent HCII and tissue-based polymerase chain reaction analysis for high-risk HPV subtypes. Of 33 women with cervical intraepithelial neoplasia (CIN) 2 or worse biopsy results, 27 biopsy specimens contained sufficient tissue to perform immunohistochemical testing (pathologist blinded as to cytologic and HCII results) for adhesion molecules beta-catenin and 21 cases for E-cadherin. RESULTS: Five of 27 specimens with CIN 2 or worse biopsy results (18.5%) had negative HCII results. All five specimens showed evidence of high-risk human papillomavirus by polymerase chain reaction analysis. All five showed full-thickness distribution via immunohistochemical staining for beta-catenin. There was sufficient tissue to examine four of five specimens for E-cadherin, and a full-thickness distribution also was documented. CONCLUSIONS: Previous research linked false-negative cytologic results in women with high-grade CIN to altered adhesion molecule distribution and impaired exfoliation, and a similar phenomenon may be responsible for false-negative HCII results in women with atypical squamous cells cytologic results and high-grade CIN.

J Low Genit Tract Dis. 2005 Apr;9(2):82-8.

Should liquid-based cytology be repeated at the time of colposcopy?

Mao C, Balasubramanian A, Koutsky LA.Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.

OBJECTIVE: To evaluate the usefulness of repeated liquid cytology at the time of colposcopy. MATERIALS AND METHODS: We screened 5,100 women with liquid-based cytology and human papillomavirus (HPV) DNA testing. Women with any abnormal cytology result including atypical squamous cells of undetermined significance (ASCUS) or a positive high-risk HPV DNA test result were referred for colposcopy. One thousand three hundred thirty-three women returned for colposcopy with repeated cytology and cervical biopsy. RESULTS: Twenty-one women had less than high-grade squamous intraepithelial lesion (HSIL) screening cytology and cervical biopsy results; however, their repeated cytology at the colposcopy visit revealed HSIL, and excisional treatment was recommended. Repeated cytology at colposcopy significantly changed the clinical management for 1.6% (21) of 1,333 women. CONCLUSIONS: As an adjunct test to colposcopy, liquid cytology was similar to conventional cytology. Given current practice patterns, repeated liquid cytology at the time of colposcopy is rarely clinically useful.

CA Cancer J Clin. 2004 Sep-Oct;54(5):248-59.

HPV communication: review of existing research and recommendations for patient education.

Anhang R, Goodman A, Goldie SJ. Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA.

The potential for human papillomavirus (HPV) DNA testing in cervical cancer prevention programs has been a topic at the forefront of cervical cancer policy discussions in recent years. To prevent some of the anxiety and psychological distress often experienced on HPV diagnosis and during the period of management, mass patient education must accompany the incorporation of HPV DNA testing into screening protocols. To contribute to a growing body of work that provides an empiric basis for development of effective counseling messages about HPV and HPV testing, this paper highlights women's most common information gaps and psychosocial concerns and describes the different perspectives offered by women's usual sources of information about HPV, including the crucial role of the clinical community in creating a shared decision making environment in which screening decisions and results can be discussed.

Publication Types:
• Review
• Review, Tutorial

Salud Publica Mex. 2003;45 Suppl 3:S388-98.

Improving cervical cancer screening in Mexico: results from the Morelos HPV Study.

Flores Y, Bishai D, Lazcano E, Shah K, Lorincz A, Hernandez M, Salmeron J. Epidemiology and Health Services Research Department, The Mexican Institute for Social Security, Cuernavaca, Morelos, Mexico.

OBJECTIVE: The purpose of this paper is to describe some of the results of the Morelos HPV Study. The main objective of the Morelos HPV Study is to evaluate the use of human papillomavirus (HPV) DNA testing, as compared to the Papanicolaou (Pap) test, for cervical cancer (CC) screening. MATERIAL AND METHODS: The Morelos HPV Study is currently being conducted in Mexico, to examine the possibility of using HPV testing for CC screening. The HPV testing of self-collected vaginal and clinician-collected cervical specimens was evaluated as part of this study. The acceptability of the HPV testing of self-collected specimens was compared to that of the Pap test. A cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) was also performed. RESULTS: The Morelos HPV Study results indicate that HPV testing has a greater sensitivity to detect cervical intraepithelial neoplasia (CIN) 2/3 and CC than the Pap test. Our results also indicate an over-all lower acceptability of the Pap test as compared to the self-collected procedure. The results of the CEA and CBA indicate that screening women between the ages of 20-80 for CC using some type of HPV testing is always more cost-effective than screening for CC using the Pap test. CONCLUSIONS: Our results suggest that self- and clinician-collected HPV testing could be used in CC prevention programs, as an effective complement or substitute for the Pap test. This paper is available too at: http://www.insp.mx/salud.index.html.

Publication Types:
• Review
• Review, Tutorial

Salud Publica Mex. 2003;45 Suppl 3:S376-87.

Screening for cervical cancer: new alternatives and research.

Lorincz AT. Digene Corporation, 1201 Clopper Road, Gaithersburg, MD 20878, USA.

Evidence for the clinical utility of human papillomavirus (HPV) DNA testing has increased over the years and has now become very convincing. Some specific uses of HPV detection are a) triage of women with cytological determinations of atypical squamous cells of undetermined significance (ASC-US) and related management strategies, b) as a marker for test of cure post-treatment, and c) most importantly, as an adjunct to cytology in routine cervical disease screening programs. There are many studies that support each of these applications and include 8 studies on ASC-US triage, 10 on test of cure and 13 on adjunctive or stand-alone HPV screening. The most notable investigation of ASC-US triage was ALTS, a randomized controlled trial of 3,488 women. With respect to routine HPV screening the combined studies included 77,000 women, providing as a histological endpoint more than 1,000 cases of high-grade cervical intraepithelial neoplasia (CIN) or cancer. Testing methods were either the Hybrid Capture 2 (HC2) test or the polymerase chain reaction (PCR) test. HPV testing of women with ASC-US cytology had on average a higher sensitivity (90%) and specificity (70%) than repeating the cytological test (sensitivity 75%, specificity 60%) and was also more sensitive than colposcopy for follow-up. As an adjunct to the Papanicolaou (Pap) cytology test in routine screening, HPV DNA testing was a more sensitive indicator for prevalent high-grade CIN than either conventional or liquid cytology. A combination of HPV DNA and Papanicolaou testing had almost 100% sensitivity and negative predictive value. The specificity of the combined tests was slightly lower than the specificity of the Papanicolaou test. One "double-negative" HPV DNA and Papanicolaou test indicated a higher prognostic assurance against risk of future CIN 3 than three subsequent negative conventional Papanicolaou tests and may safely allow three-year or longer screening intervals for such low-risk women. It appears that HPV DNA testing is on the way to becoming a common testing strategy in cervical cancer prevention programs. Research continues into approaches for improving the performance and cost-effectiveness of HPV detection methods. Hybrid Capture 3 will offer improved HPV typing capabilities and the Rapid Capture machine allows for robot-assisted HPV DNA testing, permitting greater test throughput. PCR test improvements are expected to contribute to the growth of flexible accurate and cost-effective HPV DNA tests. It is likely that improved diagnostic technology along with HPV genotyping and quantitation may provide more value in future. A particularly promising approach is to combine HPV DNA testing with expression levels of other markers such as proliferative or cell cycle regulatory proteins to subdivide HPV-positive women into those who are at greater risk of cancer and those who can be safely followed by screening at longer intervals. This paper is available too at: http://www.insp.mx/salud/index.html.

Publication Types:
• Review
• Review, Tutorial

Hpv Viruses - HPV Research Links

HPV Currents - The secret life of HPV with new facts.

HPV Research Labs - A list of UK Labs conducting research into HPV.